• Brief
  • Portfolio
  • Ask
  • Network

SUNPHARMA

Sun Pharmaceutical Industries Ltd · Pharma

₹1,872+0.1% today

OverviewResearchPeopleNews
Open deep researchGenerated 9d ago · 51 movements · 20 sources
BusinessSun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs)

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

TrajectoryRevenue compounded 12% a year over 5 years (₹33,498 cr in FY21 → ₹58,462 cr in FY26).
  • Revenue compounded 12% a year over 5 years (₹33,498 cr in FY21 → ₹58,462 cr in FY26).
  • Profit grew faster than revenue (38% vs 12% a year): operating leverage is showing.
  • EBITDA margin steady at 28% (FY26), in line with the prior three years.
  • Latest quarter (Sep 2026): revenue +12% and net profit -36% year on year.
FY26₹58,462 crRevenue₹11,509 crNet profit
020,00040,00060,000FY18FY20FY22FY24FY26
RevenueNet profit
FY2628.0%EBITDA margin
15%20%25%30%35%FY18FY20FY22FY24FY26
Sep 26₹16,199 crRevenue₹1,995 crNet profit
010,00020,000Mar 25Sep 25Mar 26Sep 26
RevenueNet profit
Balance sheetDebt/equity 0.04x as of Sep 2026 (effectively debt-free): borrowings ₹3,241 cr against net worth ₹89,280 cr.
  • Debt/equity 0.04x as of Sep 2026 (effectively debt-free): borrowings ₹3,241 cr against net worth ₹89,280 cr.
  • Working-capital days rose from 40 to 54 over three years: more cash tied up in operations.
FY26₹4,627 crBorrowings₹83,570 crNet worth
0L0.5L1LFY21FY22FY23FY24FY25FY26
BorrowingsNet worth
FY2654 daysWorking-capital days
20d40d60d80dFY20FY22FY24FY26
Cash qualityOver five years, operating cash flow was 120% of reported profit (₹52,570 cr vs ₹43,986 cr): profits are turning into cash.
  • Over five years, operating cash flow was 120% of reported profit (₹52,570 cr vs ₹43,986 cr): profits are turning into cash.
  • Cumulative free cash flow over five years: ₹41,320 cr after funding capex.
FY26₹11,509 crNet profit₹12,419 crCash from operations
05,00010,00015,000FY21FY22FY23FY24FY25FY26
Net profitCash from operations
ShareholdingPromoters cut their stake from 54.5% to 52.7% (Sep 2025 → Sep 2026).
  • Promoters cut their stake from 54.5% to 52.7% (Sep 2025 → Sep 2026).
  • Foreign institutions cut their stake from 16.6% to 14.4% (Sep 2025 → Sep 2026).
  • Domestic institutions raised their stake from 20.1% to 22.3% (Sep 2025 → Sep 2026).
Sep 2652.7%Promoters14.4%Foreign institutions22.3%Domestic institutions
0%20%40%60%Mar 24Sep 24Mar 25Sep 25Mar 26Sep 26
PromotersForeign institutionsDomestic institutions

Computed from consolidated statements compiled from annual reports and exchange filings · screener.in